Moderna, Inc. vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Moderna, Inc. trades at $196.76 (market cap $78.44B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.55 (market cap $339.46M). The key difference: Moderna, Inc. is far larger — about 231.1× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| MRNA | XDTE | |
|---|---|---|
Market Cap | $78.44B | $339.46M |
Volume | 14,597,511 | 214,614 |
Sector | Health | Income / Options Overlay |
52-Week High | $203.46 | $44.76 |
52-Week Low | $22.36 | $36.00 |
Typical Hold Time | 59 Days | 54 Days |
Enterprise Value | $74.59B | — |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →